Osteocytes, the most abundant and long-lived, yet least studied bone cell, are increasingly recognised as key controllers of bone remodelling and are implicated in many bone diseases. Our work is uncovering novel molecular and cellular pathways by which osteocytes act and survive in bone, which is generally an oxygen-deprived tissue. This will provide a rational basis to seek improved treatments of bone disease.
The osteocyte, the most abundant bone cell, likely plays a central role in bone biology and diseases, such as osteoporosis. The osteocyte product Sclerostin is a key regulator of bone mass. We are characterising novel pathways of sclerostin action via the expression of microRNAs.